COST-EFFECTIVENESS OF INTRAVITREAL AFLIBERCEPT IN TREATING NEOVASCULAR AGE-RELATED MACULAR DEGENERATION IN SWEDEN

被引：0
|
作者：
Clements, K. M. [1 ]
Hulbert, E. M. [2 ]
Panchmatia, H. R. [1 ]
Eriksson, M. [3 ]
Wittrup-Jensen, K. U. [4 ]
Nilsson, J. [5 ]
Weinstein, M. C. [6 ]
机构：
[1] OptumInsight, Cambridge, MA USA
[2] OptumInsight, Eden Prairie, MN USA
[3] Bayer AB, Solna, Sweden
[4] Bayer Pharma AG, Berlin, Germany
[5] OptumInsight, Stockholm, Sweden
[6] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA
来源：
VALUE IN HEALTH | 2013年 / 16卷 / 07期
关键词：
D O I：
10.1016/j.jval.2013.08.1168
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A506 / A506
页数：1
相关论文
共 50 条
  • [31] Cost-effectiveness analysis of brolucizumab versus aflibercept for the treatment of neovascular age-related macular degeneration (nAMD) in Italy
    Nicola Ferrante
    Daniela Ritrovato
    Rossella Bitonti
    Gianluca Furneri
    BMC Health Services Research, 22
  • [32] Cost-effectiveness of ranibizumab compared with pegaptanib in neovascular age-related macular degeneration
    Luis Javier Hernández-Pastor
    Ana Ortega
    Alfredo García-Layana
    Joaquín Giráldez
    Graefe's Archive for Clinical and Experimental Ophthalmology, 2010, 248 : 467 - 476
  • [33] Cost-effectiveness of ranibizumab compared with pegaptanib in neovascular age-related macular degeneration
    Javier Hernandez-Pastor, Luis
    Ortega, Ana
    Garcia-Layana, Alfredo
    Giraldez, Joaquin
    GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2010, 248 (04) : 467 - 476
  • [34] COST-EFFECTIVENESS OF FARICIMAB IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION IN CANADA
    Buhrer, C.
    Paulo, T.
    Diles, D.
    VALUE IN HEALTH, 2022, 25 (12) : S111 - S112
  • [35] Tolerating subretinal fluid in the treatment of neovascular age-related macular degeneration with intravitreal aflibercept
    Yildiz, Dilan
    Cakir, Akin
    Erden, Burak
    Bolukbasi, Selim
    Erdenoz, Serkan
    Elcioglu, Mustafa Nuri
    THERAPEUTIC ADVANCES IN OPHTHALMOLOGY, 2021, 13
  • [36] AFLIBERCEPT FOR THE TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
    Verner-Cole, E. A.
    Davis, S. J.
    Lauer, A. K.
    DRUGS OF TODAY, 2012, 48 (05) : 317 - 329
  • [37] Morphological changes with Intravitreal Aflibercept for Treatment Resistant Neovascular Age-Related Macular Degeneration
    Wong, Lily
    Le Hong, Thomas Hai
    Broadhead, Geoffrey
    Zhu, Meidong
    Chang, Andrew Alexander
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2015, 56 (07)
  • [38] Characteristics of patients with neovascular age-related macular degeneration who are nonresponders to intravitreal aflibercept
    Hara, Chikako
    Wakabayashi, Taku
    Toyama, Hiroshi
    Fukushima, Yoko
    Sayanagi, Kaori
    Sato, Shigeru
    Sakaguchi, Hirokazu
    Nishida, Kohji
    BRITISH JOURNAL OF OPHTHALMOLOGY, 2019, 103 (05) : 623 - 629
  • [39] One year effectiveness study of intravitreal aflibercept in neovascular age-related macular degeneration: a meta-analysis
    Guo, Michael Y.
    Cheng, Jasmine
    Etminan, Mahyar
    Zafari, Zafar
    Maberley, David
    ACTA OPHTHALMOLOGICA, 2019, 97 (01) : E1 - E7
  • [40] Comparative effectiveness of aflibercept for the treatment of patients with neovascular age-related macular degeneration
    Thomas, Michael
    Mousa, Shaymaa S.
    Mousa, Shaker A.
    CLINICAL OPHTHALMOLOGY, 2013, 7 : 495 - 500
12345